Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2023 | $140.00 → $175.00 | In-line → Outperform | Evercore ISI |
| 2/16/2023 | $155.00 → $175.00 | Outperform → Strong Buy | Raymond James |
| 2/6/2023 | $162.00 → $141.00 | Outperform → Market Perform | SVB Securities |
| 11/21/2022 | $135.00 | Hold | Truist |
| 10/11/2022 | $177.00 → $178.00 | Market Perform → Outperform | BMO Capital Markets |
| 6/29/2022 | $220.00 | Outperform | Raymond James |
| 6/24/2022 | $169.00 | Market Perform | BMO Capital Markets |
| 2/16/2022 | $201.00 → $142.00 | Market Outperform | JMP Securities |
Pfizer Inc (NYSE:PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several top-sellers. At the end of 2023, Pfizer completed its acquisition of Seagen Inc. (NASDAQ:SGEN), a biotechnology leader in transformative cancer medicines. Although Pfizer still has a few growth best-sellers, migraine therapy Nurtec and respiratory syncytial virus (RSV) vaccine, Pfizer is betting on such big business development deals to boost its annual revenue by close to $25 billion by the end of the decade. Last year, the U.S. FDA also approved Pfizer’s blood cancer therapy. But cancer is one of
Pfizer Inc. (NYSE:PFE) shares closed almost flat on Friday, but lost around 44% during 2023. Pfizer recently announced the completion of its acquisition of Seagen Inc (NASDAQ:SGEN) for $229 per share at a total value of approximately $43 billion. Pfizer recently provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen transaction. For FY24, the pharma giant expects revenue of $58.5 billion-$61.5 billion, including the expected contribution from the Seagen acquisition versus the consensus of $63.17 billion. With the recent buzz around Pfizer, some investors may be eyeing potential gains from the company’s dividends. As of now, Pfizer offers an ann
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. "As regulators' perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps." "Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i
Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete
-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2
15-12G - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
Evercore ISI upgraded Seagen from In-line to Outperform and set a new price target of $175.00 from $140.00 previously
Raymond James upgraded Seagen from Outperform to Strong Buy and set a new price target of $175.00 from $155.00 previously
SVB Securities downgraded Seagen from Outperform to Market Perform and set a new price target of $141.00 from $162.00 previously
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Seagen Inc. (NASDAQ:SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company's Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee. "We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positiv
Felix Baker, Ph.D., Appointed Chair of the Board Board Begins Search for New CEO Roger Dansey, M.D., Chief Medical Officer, Remains Interim CEO Seagen Inc. (NASDAQ:SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i
SC 13D/A - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
SC 13D/A - Seagen Inc. (0001060736) (Subject)